Liang Shan Selected Research

Lipopolysaccharides

1/2023	DMBT1 Alleviates Nasal Airway Inflammatory Response in the LPS-Induced Nasal Polyp Model.
2/2015	Tanshinone IIA therapeutically reduces LPS-induced acute lung injury by inhibiting inflammation and apoptosis in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Liang Shan Research Topics

Disease

35	Neoplasms (Cancer) 10/2023 - 09/2002
13	Infections 02/2024 - 11/2009
8	Carcinoma (Carcinomatosis) 04/2005 - 10/2002
7	Hepatocellular Carcinoma (Hepatoma) 01/2024 - 01/2017
6	Fibrosis (Cirrhosis) 01/2024 - 10/2019
6	Squamous Cell Carcinoma of Head and Neck 10/2023 - 01/2008
6	Breast Neoplasms (Breast Cancer) 01/2023 - 09/2002
4	Liver Cirrhosis (Hepatic Cirrhosis) 01/2024 - 03/2020
4	Inflammation (Inflammations) 01/2024 - 02/2015
4	Glioblastoma (Glioblastoma Multiforme) 12/2023 - 01/2015
3	Neoplasm Metastasis (Metastasis) 11/2022 - 01/2008
3	Critical Illness (Critically Ill) 11/2013 - 11/2011
3	Prostatic Neoplasms (Prostate Cancer) 05/2013 - 10/2002
3	Carcinogenesis 07/2004 - 02/2003
2	Bites and Stings (Sting) 03/2024 - 10/2023
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 10/2018
2	Liver Diseases (Liver Disease) 01/2024 - 01/2022
2	Cardiotoxicity 01/2023 - 05/2009
2	HIV Infections (HIV Infection) 01/2023 - 08/2013
2	Hematologic Neoplasms (Hematological Malignancy) 01/2017 - 01/2013
2	Sepsis (Septicemia) 02/2016 - 06/2015
2	Virus Diseases (Viral Diseases) 01/2014 - 06/2013
2	Latent Infection 01/2014 - 03/2012
2	Viremia 03/2012 - 07/2011
2	Adenoma (Adenomas) 01/2005 - 12/2003
1	Disease Progression 02/2024
1	Chronic Hepatitis C 01/2024
1	Fatty Liver 01/2024
1	Diphtheria 10/2023
1	Wounds and Injuries (Trauma) 05/2023
1	Hypothermia 01/2023
1	Nasal Polyps (Nasal Polyp) 01/2023
1	Brain Neoplasms (Brain Tumor) 01/2023
1	Pancreatic Neoplasms (Pancreatic Cancer) 11/2022
1	Body Weight (Weight, Body) 11/2022

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 10/2023 - 12/2003
9	benzocycloheptapyridineIBA 04/2005 - 10/2002
8	CarcinogensIBA 01/2006 - 10/2002
7	2- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA 04/2005 - 10/2002
6	InflammasomesIBA 02/2024 - 01/2017
6	Immunotoxins (Immunotoxin)IBA 10/2023 - 01/2013
5	anthraceneIBA 01/2006 - 10/2002
4	Cyclin D1IBA 04/2005 - 10/2002
3	CytokinesIBA 12/2022 - 03/2020
3	ErbB Receptors (EGF Receptor)IBA 03/2022 - 10/2018
3	Diphtheria ToxinIBA 03/2022 - 05/2013
3	MicroRNAs (MicroRNA)IBA 12/2020 - 04/2017
3	huaierIBA 01/2020 - 01/2017
3	Transferrin (beta 2 Transferrin)IBA 11/2010 - 01/2005
3	Proliferating Cell Nuclear Antigen (PCNA)IBA 04/2005 - 02/2003
3	Complementary DNA (cDNA)IBA 02/2005 - 10/2002
2	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2022
2	VaccinesIBA 02/2024 - 10/2017
2	Adenosine (Adenocard)FDA LinkGeneric 01/2024 - 01/2022
2	CollagenIBA 01/2024 - 05/2023
2	Coffee FDA Link 01/2024 - 01/2022
2	Caffeine (No Doz)FDA LinkGeneric 01/2024 - 01/2022
2	muconomycin AIBA 12/2023 - 01/2022
2	Matrix Metalloproteinases (MMPs)IBA 06/2023 - 05/2023
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 06/2015
2	LipopolysaccharidesIBA 01/2023 - 02/2015
2	LuciferasesIBA 11/2022 - 01/2008
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 12/2016
2	AntibodiesIBA 10/2018 - 12/2017
2	Monoclonal AntibodiesIBA 12/2017 - 05/2013
2	tanshinoneIBA 02/2015 - 09/2014
2	Contrast MediaIBA 11/2010 - 03/2007
2	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 02/2005 - 01/2005
2	QuinoxalinesIBA 02/2005 - 01/2005
2	AminesIBA 02/2005 - 07/2004
2	4-biphenylamineIBA 02/2005 - 01/2005
2	Messenger RNA (mRNA)IBA 12/2003 - 02/2003
1	Viral DNAIBA 03/2024
1	DNA (Deoxyribonucleic Acid)IBA 03/2024
1	HIV ProteaseIBA 02/2024
1	FibrinIBA 01/2024
1	EnzymesIBA 01/2024
1	Protective AgentsIBA 01/2024
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2024
1	Interferon Type IIBA 10/2023
1	InterferonsIBA 10/2023
1	Interleukin-15 (Interleukin 15)IBA 10/2023
1	Interleukin-7 (Interleukin 7)IBA 10/2023
1	Interleukin-6 (Interleukin 6)IBA 01/2023
1	Trastuzumab (Herceptin)FDA Link 01/2023
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2022
1	Simvastatin (Zocor)FDA LinkGeneric 11/2022
1	Peptide Hydrolases (Proteases)FDA Link 10/2022
1	Antiviral Agents (Antivirals)IBA 10/2022
1	Pathogen-Associated Molecular Pattern MoleculesIBA 10/2022
1	Pattern Recognition ReceptorsIBA 10/2022
1	Neoplasm Antigens (Tumor Antigens)IBA 03/2022
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 03/2022

Therapy/Procedure

20	Therapeutics 12/2022 - 10/2002
3	Lasers (Laser) 01/2024 - 12/2016
3	Drug Therapy (Chemotherapy) 10/2018 - 02/2012
3	Immunotherapy 12/2017 - 01/2014
3	Highly Active Antiretroviral Therapy (HAART) 06/2013 - 11/2009
2	Tracheotomy 11/2013 - 09/2013
2	Intravenous Administration 01/2008 - 03/2007